NO963919L - Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler - Google Patents

Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler

Info

Publication number
NO963919L
NO963919L NO963919A NO963919A NO963919L NO 963919 L NO963919 L NO 963919L NO 963919 A NO963919 A NO 963919A NO 963919 A NO963919 A NO 963919A NO 963919 L NO963919 L NO 963919L
Authority
NO
Norway
Prior art keywords
hla
molecules
complex
peptides derived
isolated peptides
Prior art date
Application number
NO963919A
Other languages
English (en)
Norwegian (no)
Other versions
NO963919D0 (no
Inventor
Alan Townsend
Judy Bastin
Thierry Boon-Falleur
Pierre Van Der Bruggen
Pierre Coulie
Thomas Gajewski
Cornelis Melief
M W Visseren
W M Kast
Original Assignee
Ludwig Inst Cancer Res
Univ Oxford
Univ Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,186 external-priority patent/US5585461A/en
Application filed by Ludwig Inst Cancer Res, Univ Oxford, Univ Leiden filed Critical Ludwig Inst Cancer Res
Publication of NO963919D0 publication Critical patent/NO963919D0/no
Publication of NO963919L publication Critical patent/NO963919L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO963919A 1994-03-24 1996-09-19 Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler NO963919L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/217,186 US5585461A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/261,160 US5591430A (en) 1994-03-24 1994-06-17 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US08/290,381 US5851523A (en) 1994-03-24 1994-08-15 Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof
PCT/US1995/003657 WO1995025740A1 (en) 1994-03-24 1995-03-22 Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules

Publications (2)

Publication Number Publication Date
NO963919D0 NO963919D0 (no) 1996-09-19
NO963919L true NO963919L (no) 1996-11-20

Family

ID=27396385

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963919A NO963919L (no) 1994-03-24 1996-09-19 Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler

Country Status (16)

Country Link
US (1) US5851523A (de)
EP (2) EP0960622A3 (de)
JP (1) JP3536179B2 (de)
CN (1) CN1151170C (de)
AT (1) ATE198336T1 (de)
AU (1) AU698781B2 (de)
CA (1) CA2186004C (de)
DE (1) DE69519748T2 (de)
DK (1) DK0804483T3 (de)
ES (1) ES2154728T3 (de)
FI (1) FI963779A0 (de)
GR (1) GR3035636T3 (de)
NO (1) NO963919L (de)
NZ (1) NZ283587A (de)
PT (1) PT804483E (de)
WO (1) WO1995025740A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5686068A (en) * 1994-03-24 1997-11-11 Ludwig Institute For Cancer Research Isolated peptides derived from MAGE-2, cytolytic T cells specific to complexes of peptide and HLA-A2 molecules, and uses thereof
US5587289A (en) * 1995-03-14 1996-12-24 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereof
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
DE69610483T2 (de) * 1996-01-18 2001-06-13 Aventis Pharma Deutschland Gmbh In kunstlisches Rekombinantes Substrat rAGG-1 und nativem Aggrecan zum Studium der proteolytischen Wirkung von 'Aggrecanase' in Zellkultursystemen
WO1998058951A1 (en) * 1997-06-23 1998-12-30 Ludwig Institute For Cancer Research Isolated nona- and decapeptides which bind to hla molecules, and the use thereof
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5965535A (en) 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
US7090847B1 (en) * 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
EP3184637A1 (de) * 1999-09-09 2017-06-28 Merck Sharp & Dohme Corp. Komplexe aus säugetier-interleukin-12 p40 und interleukin b30, antikörper, verwendung in pharmazeutischen zusammensetzungen
KR100894359B1 (ko) * 1999-09-09 2009-04-22 쉐링 코포레이션 포유동물의 사이토카인, 이와 관련된 시약 및 이러한 시약의 사용 방법
EP1222274A2 (de) * 1999-10-19 2002-07-17 Ludwig Institute For Cancer Research Vom mage-12 abgeleitete antigene peptide und deren verwendungen
US6897288B1 (en) 1999-10-19 2005-05-24 Ludwig Institute For Cancer Research Mage-A12 antigenic peptides and uses thereof
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US8562970B2 (en) * 2003-10-08 2013-10-22 Sanofi Pasteur Limited Modified CEA/B7 vector
EP2188017A2 (de) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Verwendung von glucagon (1-29) allein oder in kombination mit neuropeptid w30 als therapeutisches mittel
CN106117334B (zh) * 2016-06-24 2020-02-11 秦皇岛未名健康城开发有限公司 一种肿瘤抗原mage3的ctl识别表位肽及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
EP1704868A1 (de) * 1992-08-07 2006-09-27 Pharmexa Inc. HLA Bindepeptide und ihre Verwendungen
US5519117A (en) * 1992-12-22 1996-05-21 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
KR960700739A (ko) * 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)

Also Published As

Publication number Publication date
DK0804483T3 (da) 2001-02-12
CN1150805A (zh) 1997-05-28
PT804483E (pt) 2001-06-29
EP0960622A3 (de) 1999-12-22
JP3536179B2 (ja) 2004-06-07
EP0804483A4 (de) 1998-05-20
DE69519748D1 (de) 2001-02-01
CN1151170C (zh) 2004-05-26
WO1995025740A1 (en) 1995-09-28
ATE198336T1 (de) 2001-01-15
US5851523A (en) 1998-12-22
EP0804483B1 (de) 2000-12-27
CA2186004C (en) 2008-09-23
FI963779L (fi) 1996-09-23
AU698781B2 (en) 1998-11-05
AU2192895A (en) 1995-10-09
NO963919D0 (no) 1996-09-19
FI963779A7 (fi) 1996-09-23
EP0960622A2 (de) 1999-12-01
ES2154728T3 (es) 2001-04-16
NZ283587A (en) 1998-04-27
FI963779A0 (fi) 1996-09-23
JPH10504518A (ja) 1998-05-06
CA2186004A1 (en) 1995-09-28
EP0804483A1 (de) 1997-11-05
DE69519748T2 (de) 2001-10-18
GR3035636T3 (en) 2001-06-29

Similar Documents

Publication Publication Date Title
NO963919L (no) Isolerte peptider avledet fra MAGE-tumorrejeksjonsantigenforlöpere som komplekserer med HLA-A2-molekyler
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
DE69938302D1 (de) Neisseria meningitidis antigene und zusammenstellungen
PL374311A1 (en) Methods for purifying protein
ES2129622T3 (es) Receptores para interleuquina-10 de mamifero.
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
NO995182D0 (no) Pattedyrcytokinlignende faktor 7
SE9602496D0 (sv) Method and means for producing a fibrinogen binding protein and its use in biotechnology
DE69333382D1 (de) Hyaluronan rezeptor (rezeptor durch hyaluronan verurzachte bewelichkeit) und hyaluronan bindende peptide
DE69735583D1 (de) Semisynthetisches verfahren zur herstellung von didemninanalogen
EP0990703A4 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
ATE316577T1 (de) Das goodpasture-antigen bindende protein
WO2001029220A3 (en) Mage-a12 antigenic peptides and uses thereof
DE69128039D1 (de) Allergene aus roggenspreupollen
AR022150A1 (es) Acidos nucleicos derivados de monocitos y composiciones y metodos relacionados
BR9911609A (pt) Proteìnas e genes de moraxella catarrhalis, antìgenos, anticorpos e usos
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof